Last reviewed · How we verify
Placebo Comparator: Placebo control
Placebo is an inert substance with no active pharmacological mechanism; it serves as a control comparator in clinical trials.
At a glance
| Generic name | Placebo Comparator: Placebo control |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Placebo acts as a negative control to establish baseline disease progression and assess the magnitude of treatment effect independent of active drug mechanisms. Any observed clinical benefit in placebo groups is attributed to natural disease course, regression to the mean, and psychosocial factors including the placebo effect itself.
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure (NA)
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: